Chardan Capital Issues Pessimistic Forecast for CAMP4 Therapeutics (NASDAQ:CAMP) Stock Price

CAMP4 Therapeutics (NASDAQ:CAMP) had its price target decreased by stock analysts at Chardan Capital from $6.50 to $6.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the Wireless communications provider’s stock. Chardan Capital’s price target points to a potential upside of 55.84% from the stock’s previous close.

Several other analysts have also weighed in on CAMP. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $5.00 to $9.00 in a research note on Tuesday, June 16th. UBS Group set a $15.00 target price on CAMP4 Therapeutics in a research note on Friday, August 14th. Zacks Research raised shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Piper Sandler restated an “overweight” rating and issued a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Finally, Weiss Ratings raised shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.71.

CAMP4 Therapeutics Stock Down 1.8%

Shares of CAMP4 Therapeutics stock opened at $3.85 on Tuesday. The stock has a market cap of $241.59 million, a P/E ratio of -1.66 and a beta of 0.27. The business’s 50 day moving average is $4.09 and its 200-day moving average is $4.30. CAMP4 Therapeutics has a 12-month low of $2.85 and a 12-month high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The firm had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. On average, sell-side analysts expect that CAMP4 Therapeutics will post -0.57 EPS for the current year.

Insider Activity at CAMP4 Therapeutics

In related news, Director Richard Young acquired 16,378 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were purchased at an average price of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the acquisition, the director owned 186,388 shares of the company’s stock, valued at approximately $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Andrew Schwab sold 400,000 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $4.04, for a total value of $1,616,000.00. Following the transaction, the director directly owned 2,033,270 shares in the company, valued at approximately $8,214,410.80. This trade represents a 16.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have purchased 46,031 shares of company stock worth $99,051 and have sold 593,613 shares worth $2,504,037. 21.69% of the stock is owned by corporate insiders.

Institutional Trading of CAMP4 Therapeutics

Several institutional investors have recently made changes to their positions in CAMP. Jefferies Financial Group Inc. purchased a new stake in shares of CAMP4 Therapeutics during the 4th quarter valued at $70,000. Bank of America Corp DE bought a new stake in shares of CAMP4 Therapeutics during the 2nd quarter valued at $78,000. Deutsche Bank AG purchased a new position in CAMP4 Therapeutics during the second quarter worth about $138,000. Bank of New York Mellon Corp purchased a new position in CAMP4 Therapeutics in the second quarter worth $365,000. Finally, EcoR1 Capital LLC bought a new position in CAMP4 Therapeutics during the fourth quarter valued at approximately $1,992,000.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases caused by insufficient expression of essential proteins. The company’s approach is designed to increase the body’s production of naturally occurring proteins by activating the transcription of specific genes, potentially addressing the underlying cause of disease rather than only treating symptoms.

CAMP4’s technology platform uses RNA-based gene-activation therapeutics intended to target regulatory regions associated with disease-relevant genes.